Biogen, Eisai Struggle With BAN2401 In Alzheimer’s Disease Treatment | Investors.com

“Biogen (BIIB) and Japanese partner Eisai may be at odds in developing a treatment for Alzheimer’s disease, an analyst said Monday after a paradoxical presentation last week. The two are collaborating on BAN2401, an experimental Alzheimer’s disease drug. But test results unveiled last week showed BAN2401 may only work in a small subset of patients. Leerink analyst Geoffrey Porges suggested Biogen would be better off focusing on its own drug, aducanumab. Most companies would likely advance BAN2401 into Phase 3 studies, Porges said in a report to clients. But aducanumab seemingly has a better profile than BAN2401. Both belong to the same class of drugs which aim to reduce the buildup of toxic plaque in the brain.”
Read the full story at investors.com